Document Detail


Cold lymphocytotoxic antibodies in systemic lupus erythematosus.
MedLine Citation:
PMID:  6331685     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Optimum conditions were established for the assay of cold lymphocytotoxic antibodies (cLCTA) in serum from patients with systemic lupus erythematosus (SLE). The optimum temperature of the incubation step with complement was 15 degrees C. For target cells incubated with dextran a significantly higher percentage of damaged cells (p less than 0.005), a faster rate of cell damage (p less than 0.001) and a requirement for less complement was observed than for target cells not incubated with dextran. Under optimum conditions in the cytotoxicity assay, 62% of SLE sera damaged more than 60% of the target cells, whereas 73% of the sera from control donors damaged less than 20% of the target cells. In multiple serum samples obtained during follow-up of 30 patients with SLE, the serum cytotoxic activity or titer of cLCTA fluctuated and did not relate to clinical symptoms of disease activity. In sera obtained during active disease the cytotoxic activity was related to the anti-dsDNA antibody level and with levels of circulating immune complexes measured by the Raji cell assay and the indirect granulocyte phagocytosis test. We found no restricted reactivity of cLCTA against phenotypically distinct T-lymphocyte subpopulations with different immunoregulatory functions. The reactivity pattern of cLCTA towards the various T-lymphocyte subpopulations was not related to disease activity. We conclude that cLCTA in patients with SLE represent an epiphenomenon, being the result of a hyperreactive B-cell system rather than the cause of the disease.
Authors:
R H Derksen; H J Schuurman; C J Heijnen; A M Meekes; R Broekhuizen; L Kater
Related Documents :
2502505 - T-cell markers in tumor-infiltrating lymphocytes of head and neck cancer.
18855225 - Increased surface receptor fas (cd95) levels on cd4+ lymphocytes in patients with prima...
12563705 - B cell loss leading to remission in severe systemic lupus erythematosus.
2206205 - Behaviour of lymphocyte subsets in response to immunotherapy with propionibacterium avi...
6790625 - A novel human t cell antigen preferentially expressed on mature t cells and shared by b...
11807815 - Inhibition of caco-2 cell proliferation by all-trans retinoic acid: role of insulin-lik...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Vox sanguinis     Volume:  46     ISSN:  0042-9007     ISO Abbreviation:  Vox Sang.     Publication Date:  1984  
Date Detail:
Created Date:  1984-09-14     Completed Date:  1984-09-14     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0413606     Medline TA:  Vox Sang     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  366-76     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Antilymphocyte Serum / analysis*
Cold Temperature
Complement C3 / immunology
Complement C4 / immunology
Cytotoxicity Tests, Immunologic
DNA
Female
Humans
Isoantibodies / immunology
Lupus Erythematosus, Systemic / immunology*
Male
Middle Aged
Receptors, Fc / analysis
T-Lymphocytes / classification,  immunology
Chemical
Reg. No./Substance:
0/Antilymphocyte Serum; 0/Complement C3; 0/Complement C4; 0/Isoantibodies; 0/Receptors, Fc; 9007-49-2/DNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Characteristics of antitumor immunity in different forms of chronic gastritis
Next Document:  Scoliosis: diagnosis and current treatment.